Balthasar Luzius Hug

Balthasar Luzius Hug

Auto-generated profile, based on publicly available information

Balthasar Luzius Hug

Faculty for Health Sciences and Medicine University of Lucerne Lucerne Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Medicine
Verified
Journal Article
Open access
PDF file
JRJan A. Roth
Jan A. Roth
CCCarl Chrobak
Carl Chrobak
SSSabine Schädelin
Sabine Schädelin
BHBalthasar L. Hug
Balthasar L. Hug
The laboratory-based model for end-stage liver disease (MELD) score reflects the function of the kidney, liver, and extrinsic coagulation pathway and might be used as a general prognostic tool for the assessment of patients. We therefore aimed to investigate a potential association of the MELD score with mortality, length of hospital stay (LOS), and disease burden in a general patient population. We performed a retrospective observational study at a tertiary referral center. From January 2012 through December 2013, all consecutive inpatients aged 18 years were eligible for the study; patients with missing MELD parameters on hospital admission and/or treatments influencing the international normalized ratio, that is, novel oral anticoagulants and vitamin K antagonists, were excluded. The MELD score on hospital admission was calculated retrospectively. The primary outcome measure was in-hospital all-cause mortality; secondary outcome measures were LOS and the number of comorbidities. A total of 39,323 inpatients were included in the final analysis. On admission, MELD scores of 15 to 19, 20 to 29, and ≥30 points (reference <15 points) showed increased hazard ratios (HRs) for in-hospital mortality in uni- and multivariable analysis with an adjusted HR of 2.52 (95% confidence interval [CI], 1.81–3.49; P < .001), 2.70 (95% CI, 1.89–3.84; P < .001), and 8.00 (95% CI, 3.91–16.39; P < .001), respectively. Increased MELD scores of 15 to 19, 20 to 29, and ≥30 points were positively associated with LOS and the number of comorbidities in uni- and multivariable analysis. In our study population consisting of adult inpatients, the MELD score on hospital admission was significantly associated with mortality, LOS, and the number of comorbidities. We suggest to prospectively validate the MELD score in inpatients as part of clinical decision support systems.

11 August 2025 in BMC Cancer
Verified
Journal Article
Open access
LALauris Annatha Mariam Auch
Lauris Annatha Mariam Auch
CSChloé Sieber
Chloé Sieber
DLDirk Lehnick
Dirk Lehnick
BHBalthasar L. Hug
Balthasar L. Hug
The objective of this study was to analyze immune-related adverse events (irAEs) in a real-world data sample and examine the differences in incidence between affected organ systems, irAE severity, therapeutic agent, and gender. We retrospectively analyzed all consecutive patients treated with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibodies, anti-programmed death 1 (PD-1) inhibitors, and programmed death-ligand 1 (PD-L1) inhibitors between January 2020 and May 2023 in a tertiary referral center in Switzerland. IrAEs documented in the electronic health records (EHR) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) and analyzed descriptively. Among the 500 patients, 196 (39.2%) were female. Treatments included pembrolizumab (51.2%), atezolizumab (20.2%), nivolumab (14.4%), durvalumab (6.4%), ipilimumab in combination with nivolumab (4.8%), cemiplimab (1.4%), avelumab (1.2%), and ipilimumab (0.4%). N = 216 (43.2%) patients had ≥ 1 irAEs (females: 47.4%; males: 40.5%). Severe (≥ grade 3) irAEs were reported in 13.6% of patients. The following irAE incidences were found: dermatological (15.2%), gastrointestinal (13.0%), endocrine (10.8%), musculoskeletal (4.8%), pulmonary (3.8%), systemic (3.6%), neurological (2.6%), cardiac (1.4%), renal (1.4%), hematological (0.6%), and ocular (0.2%). Nearly half of the patients experienced ≥ 1 irAEs, of which one-third severe. Females experienced more irAEs than males, above all due to a higher incidence of grade 1 irAEs. Only about half of the irAEs were reported as coded diagnosis. Further prospective studies on irAEs are warranted using structured documentation. The online version contains supplementary material available at 10.1186/s12885-025-14733-5.

18 December 2020 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
PDF file
TSThomas Sutter
Thomas Sutter
JRJan A Roth
Jan A Roth
KCKieran Chin-Cheong
Kieran Chin-Cheong
BHBalthasar L Hug
Balthasar L Hug
JVJulia E Vogt
Julia E Vogt
Unplanned hospital readmissions are a burden to patients and increase healthcare costs. A wide variety of machine learning (ML) models have been suggested to predict unplanned hospital readmissions. These ML models were often specifically trained on patient populations with certain diseases. However, it is unclear whether these specialized ML models—trained on patient subpopulations with certain diseases or defined by other clinical characteristics—are more accurate than a general ML model trained on an unrestricted hospital cohort. In this study based on an electronic health record cohort of consecutive inpatient cases of a single tertiary care center, we demonstrate that accurate prediction of hospital readmissions may be obtained by general, disease-independent, ML models. This general approach may substantially decrease the cost of development and deployment of respective ML models in daily clinical routine, as all predictions are obtained by the use of a single model.

17 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJan A. Roth
Jan A. Roth
AWAndreas F. Widmer
Andreas F. Widmer
SSSarah Tschudin Sutter
Sarah Tschudin Sutter
MDMarc Dangel
Marc Dangel
RFReno Frei
Reno Frei
BHBalthasar L. Hug
Balthasar L. Hug
Automated laboratory-based prediction models may support clinical decisions in Staphylococcus aureus bloodstream infections (BSIs), which carry a particularly high mortality. Small studies indicated that the laboratory-based Model for End-stage Liver Disease (MELD) score is a risk factor for mortality in critically ill patients with infections. For S. aureus BSIs, we therefore aimed to assess a potential association of the MELD score with mortality. In this single-centre observational study, all consecutive patients with a first episode of methicillin-susceptible S. aureus BSI occurring between 2001 and 2013 were eligible. Relevant patient data were retrieved from our prospective in-house BSI database. We assessed the association of the MELD score at day of BSI onset (range ± two days) with 30-day all-cause mortality using uni- and multivariable logistic regression analysis. 561 patients were included in the final analysis. The MELD score at BSI onset was associated with 30-day mortality in S. aureus BSIs (odds ratio per 1-point increase, 1.06; 95% confidence interval, 1.03‒1.09; P < 0.001). After adjustment for relevant patient and infection characteristics, an increased MELD score remained a predictor of 30-day mortality (adjusted odds ratio per 1-point increase, 1.05; 95% confidence interval, 1.01‒1.08; P = 0.005). In our study population, the MELD score at BSI onset was an independent predictor of mortality in S. aureus BSIs. We therefore suggest to prospectively validate the MELD score as part of clinical decision support systems in inpatients with suspected or confirmed BSI.

20 September 2018 in JAMIA Open
Verified
Journal Article
Open access
PDF file
JRJan A Roth
Jan A Roth
NGNicole Goebel
Nicole Goebel
TSThomas Sakoparnig
Thomas Sakoparnig
SNSimon Neubauer
Simon Neubauer
EKEleonore Kuenzel-Pawlik
Eleonore Kuenzel-Pawlik
DSDamian Spyra
Damian Spyra
We describe a scalable platform for research-oriented analyses of routine data in hospitals, which evolved from a state-of-the-art business intelligence architecture for enterprise resource planning. This platform involves an in-memory database management system for data modeling and analytics and a high-performance cluster for more computing-intensive analytical tasks. Setting up platforms for research-oriented analyses is a highly dynamic, time-consuming, and costly process. In some health care institutions, effective research platforms may be derived from existing business intelligence systems.

27 February 2024 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Open access
NSNicole Schönenberger
Nicole Schönenberger
ABAnne-Laure Blanc
Anne-Laure Blanc
BHBalthasar L. Hug
Balthasar L. Hug
MHManuel Haschke
Manuel Haschke
AGAljoscha N. Goetschi
Aljoscha N. Goetschi
CMCarla Meyer-Massetti
Carla Meyer-Massetti